LECT1 (leukocyte cell derived chemotaxin 1) commonly known as chondromodulin-I (CHM-1), is a glycoprotein which is specific to cartilage. This gene is localized to human chromosome 13q14-21.
Synonyms: Anti-BRICD3; Anti-CHM-I; Anti-CHM1; Anti-LECT1; Anti-MYETS1
Storage: -20C
Application: All Prestige Antibodies Powered by Atlas Antibodies are developed and validated by the Human Protein Atlas (HPA) project (www.proteinatlas.org)and as a result, are supported by the most extensive characterization in the industry. The Human Protein Atlas project can be subdivided into three efforts: Human Tissue Atlas, Cancer Atlas, and Human Cell Atlas. The antibodies that have been generated in support of the Tissue and Cancer Atlas projects have been tested by immunohistochemistry against hundreds of normal and disease tissues and through the recent efforts of the Human Cell Atlas project, many have been characterized by immunofluorescence to map the human proteome not only at the tissue level but now at the subcellular level. These images and the collection of this vast data set can be viewed on the Human Protein Atlas (HPA) site by clicking on the Image Gallery link. To view these protocols and other useful information about Prestige Antibodies and the HPA, visit sigma.com/prestige.
Biochem Physiol Actions: LECT1 (leukocyte cell derived chemotaxin 1) is involved in the development of precursor of tumor cells and is associated with site of tumor development in chondrosarcomas. This protein is linked with chondrocyte growth and prevents the formation of tube in endothelial cells. It inhibits angiogenesis in cartilage, and it inhibits tumor growth in HT-29 colon adenocarcinoma cell line. Thus, it might have a therapeutic potential in case of solid tumors. Along with endostatin, it is responsible for maintaining the vascularity of cartilage. It preserves the avascularity of the inner meniscus by functioning as an anti-angiogenic factor.
Legal Information: Prestige Antibodies is a registered trademark of Sigma-Aldrich Co. LLC